Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P05412 (
c-Jun
)
11,453
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The transcription factor
PU.1
is necessary for the development of multiple hematopoietic lineages and contributes to the activity of the immunoglobulin kappa 3' enhancer. A variety of proteins bind to the 3' enhancer (
PU.1
, PIP, ATF1, CREM, c-Fos,
c-Jun
, and E2A), but the mechanism of 3'-enhancer activity and the proteins necessary for its activity are presently unclear. We show here that
PU.1
participates with other transcription factors in forming a higher-order complex with 3'-enhancer DNA sequences. Each protein is necessary for formation of this complex. Individually, transcription factors that bind to the 3' enhancer do not appreciably stimulate transcription in a cell type in which the 3' enhancer is normally silent (NIH 3T3). However, mixture of multiple transcription factors (
PU.1
, PIP, c-Fos, and
c-Jun
) can greatly activate the enhancer.
PU.1
is necessary for maximal enhancer activity, but mutants of
PU.1
that lack the transcriptional activation domain are nearly as efficient at stimulating enhancer activity as the wild-type
PU.1
protein.
PU.1
apparently can activate transcription by playing an architectural role in interactions with other transcription factors.
...
PMID:PU.1 can participate in an active enhancer complex without its transcriptional activation domain. 899 Jan 72
Expression of interstitial collagenase (MMP-1) has been detected in stromal fibroblasts of various malignant tumors. Here, we have studied the effect of three structurally different ETS transcription factors (ETS-1, ERGB/Fli-1, and
PU.1
) on MMP-1 promoter activity in NIH3T3 fibroblasts. ETS-1 increased the activity of 3.8 kb MMP-1 promoter construct up to tenfold, while ERGB/Fli-1 or
PU.1
alone had no marked effect on basal promoter activity. ETS-1 also markedly potentiated enhancement of MMP-1 promoter by both
c-Jun
and JunB, whereas ERGB/Fli-1 augmented only the effect of
c-Jun
. Interestingly,
PU.1
abolished induction of MMP-1 promoter by both
c-Jun
and JunB. Stimulation of MMP-1 promoter by 12-O-tetradecanoyl phorbol-13-acetate and okadaic acid was differentially augmented by ETS-1 and ERGB/Fli-1, and abrogated by
PU.1
. Co-transfection studies with MMP-1 promoter 5'-deletion constructs revealed that AP-1 site was necessary for
PU.1
-elicited suppression. As compared to control cell lines,
PU.1
-positive stable cells exhibited clearly weaker binding of
c-Jun
and JunD containing AP-1 complexes to MMP-1 promoter AP-1 element, as well as marked reduction in basal level and induction of c-jun mRNA by 12-O-tetradecanoyl phorbol-13-acetate and okadaic acid, suggesting a novel mechanism for
PU.1
-mediated inhibition of AP-1 dependent gene expression. These results show that three structurally distinct ETS transcription factors differently modulate AP-1 dependent upregulation of MMP-1 gene expression.
...
PMID:Differential regulation of interstitial collagenase (MMP-1) gene expression by ETS transcription factors. 917 63
Macrosialin is a transmembrane glycoprotein that is highly expressed in macrophages. In the present studies, macrosialin mRNA levels are shown to be markedly up-regulated during macrophage differentiation of bone marrow progenitor cells in response to macrophage colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. To investigate the mechanisms responsible for regulation of macrosialin expression, we have isolated the macrosialin gene and performed an initial analysis of its transcriptional regulatory elements. The macrosialin promoter and 7.0 kilobase pairs of 5'-flanking information direct high levels of reporter gene activity in monocyte/macrophage-like cells, but little or no expression in nonmyeloid cells. This pattern of expression is dependent on regulatory elements located between -7.0 and -2.5 kilobase pairs from the transcriptional start site that exhibit strong enhancer activity in macrophages and repressor activity in nonmyeloid cells. Analysis of the proximal macrosialin promoter indicates that combinatorial interactions between at least four classes of transcriptional activators, including
PU.1
/Spi-1 and members of the AP-1 family are required for basal promoter function.
PU.1
/Spi-1 and
c-Jun
act synergistically to activate the macrosialin promoter in a nonmyeloid cell line, suggesting that combinatorial interactions between these proteins are involved in regulating macrosialin expression during macrophage differentiation.
...
PMID:The macrosialin promoter directs high levels of transcriptional activity in macrophages dependent on combinatorial interactions between PU.1 and c-Jun. 947
The ETS domain transcription factor
PU.1
is necessary for the development of monocytes and regulates, in particular, the expression of the monocyte-specific macrophage colony-stimulating factor (M-CSF) receptor, which is critical for monocytic cell survival, proliferation, and differentiation. The bZIP transcription factor
c-Jun
, which is part of the AP-1 transcription factor complex, is also important for monocytic differentiation, but the monocyte-specific M-CSF receptor promoter has no AP-1 consensus binding sites. We asked the question of whether
c-Jun
could promote the induction of the M-CSF receptor by collaborating with
PU.1
. We demonstrate that
c-Jun
enhances the ability of
PU.1
to transactivate the M-CSF receptor promoter as well as a minimal thymidine kinase promoter containing only
PU.1
DNA binding sites.
c-Jun
does not directly bind to the M-CSF receptor promoter but associates via its basic domain with the ETS domain of
PU.1
. Consistent with our observation that AP-1 binding does not contribute to
c-Jun
coactivation is the observation that the activation of
PU.1
by
c-Jun
is blocked by overexpression of c-Fos. Phosphorylation of
c-Jun
by
c-Jun
NH2-terminal kinase on Ser-63 and -73 does not alter the ability of
c-Jun
to enhance
PU.1
transactivation. Activated Ras enhances the transcriptional activity of
PU.1
by up-regulating
c-Jun
expression without changing the phosphorylation pattern of
PU.1
. The activation of
PU.1
by Ras is blocked by a mutant
c-Jun
protein lacking the basic domain. The expression of this mutant form of
c-Jun
also completely blocks 12-O-tetradecanoylphorbol-13-acetate-induced M-CSF receptor promoter activity during monocytic differentiation. We propose therefore that
c-Jun
acts as a
c-Jun
NH2-terminal kinase-independent coactivator of
PU.1
, resulting in M-CSF receptor expression and development of the monocytic lineage.
...
PMID:c-Jun is a JNK-independent coactivator of the PU.1 transcription factor. 998 37
SPI-B is a B lymphocyte-specific Ets transcription factor that shares a high degree of similarity with
PU.1
/SPI-1. In direct contrast to
PU.1
(-/-) mice that die in utero and lack monocytes, neutrophils, B cells, and T cells, Spi-B-/- mice are viable and exhibit a severe B cell proliferation defect. Since
PU.1
is expressed at wild type levels in Spi-B-/- B cells, the mutant mice provide genetic evidence that SPI-B and
PU.1
have at least some non-redundant roles in B lymphocytes. To begin to understand the molecular basis for these defects, we delineated functional domains of SPI-B for comparison to those of
PU.1
. By using a heterologous co-transfection system, we identified two independent transactivation domains in the N terminus of SPI-B. Interestingly, only one of these domains (amino acids 31-61), a proline/serine/threonine-rich region, unique among Ets proteins, is necessary for transactivation of the immunoglobulin lambda light chain enhancer. This transactivation motif is in marked contrast to
PU.1
, which contains acidic and glutamine-rich domains. In addition, we describe a functional
PU.1
site within the c-FES promoter which SPI-B fails to bind efficiently and transactivate. Finally, we show that SPI-B interacts with the
PU.1
cofactors Pip, TBP,
c-Jun
and with lower affinity to nuclear factor interleukin-6beta and retinoblastoma. Taken together, these data suggest that SPI-B binds DNA with a different affinity for certain sites than
PU.1
and harbors different transactivation domains. We conclude that SPI-B may activate unique target genes in B lymphocytes and interact with unique, although currently unidentified, cofactors.
...
PMID:SPI-B activates transcription via a unique proline, serine, and threonine domain and exhibits DNA binding affinity differences from PU.1. 1019 96
The process through which multipotential hematopoietic cells commit to distinct lineages involves the induction of specific transcription factors.
PU.1
(also known as Spi-1) and GATA-1 are transcription factors essential for the development of myeloid and erythroid lineages, respectively. Overexpression of
PU.1
and GATA-1 can block differentiation in lineages in which they normally are down-regulated, indicating that not only positive but negative regulation of these factors plays a role in normal hematopoietic lineage development. Here we demonstrate that a region of the
PU.1
Ets domain (the winged helix-turn-helix wing) interacts with the conserved carboxyl-terminal zinc finger of GATA-1 and GATA-2 and that GATA proteins inhibit
PU.1
transactivation of critical myeloid target genes. We demonstrate further that GATA inhibits binding of
PU.1
to
c-Jun
, a critical coactivator of
PU.1
transactivation of myeloid promoters. Finally,
PU.1
protein can inhibit both GATA-1 and GATA-2 transactivation function. Our results suggest that interactions between
PU.1
and GATA proteins play a critical role in the decision of stem cells to commit to erythroid vs. myeloid lineages.
...
PMID:Negative cross-talk between hematopoietic regulators: GATA proteins repress PU.1. 1041 39
Glucocorticoid drugs suppress tumor necrosis factor-alpha (TNF-alpha) synthesis by activated monocyte/macrophages, contributing to an anti-inflammatory action in vivo. In lipopolysaccharide (LPS)-activated human monocytic THP-1 cells, glucocorticoids acted primarily on the TNF-alpha promoter to suppress a burst of transcriptional activity that occurred between 90 min and 3 h after LPS exposure. LPS increased nuclear
c-Jun
/ATF-2, NF-kappaB(1)/Rel-A, and Rel-A/C-Rel transcription factor complexes, which bound specifically to oligonucleotide sequences from the -106 to -88 base pair (bp) region of the promoter. The glucocorticoid, dexamethasone, suppressed nuclear binding activity of these complexes prior to and during the critical phase of TNF-alpha transcription. Site-directed mutagenesis in TNF-alpha promoter-luciferase reporter constructs showed that the adjacent
c-Jun
/ATF-2 (-106 to -99 bp) and NF-kappaB (-97 to -88 bp) binding sites each contributed to the LPS-stimulated expression. Mutating both sites largely prevented dexamethasone from suppressing TNF-alpha promoter-luciferase reporters. LPS exposure also increased nuclear Egr-1 and
PU.1
abundance. The Egr-1/Sp1 (-172 to -161 bp) binding sites and the
PU.1
-binding Ets site (-116 to -110 bp) each contributed to the LPS-stimulated expression but not to glucocorticoid response. Dexamethasone suppressed the abundance of the c-Fos/
c-Jun
complex in THP-1 cell nuclei, but there was no direct evidence for c-Fos/
c-Jun
transactivation through sites in the -172 to -52 bp region. Small contributions to glucocorticoid response were attributable to promoter sequences outside the -172 to -88 bp region and to sequences in the TNF-alpha 3'-untranslated region. We conclude that glucocorticoids suppress LPS-stimulated secretion of TNF-alpha from human monocytic cells largely through antagonizing transactivation by
c-Jun
/ATF-2 and NF-kappaB complexes at binding sites in the -106 to -88 bp region of the TNF-alpha promoter.
...
PMID:Glucocorticoids suppress tumor necrosis factor-alpha expression by human monocytic THP-1 cells by suppressing transactivation through adjacent NF-kappa B and c-Jun-activating transcription factor-2 binding sites in the promoter. 1074 79
Signal transduction by the antigen receptor complexes is critical for developmental progression of B-lymphocytes, which are defined by assembly and sequential expression of immunoglobulin genes, which in turn are regulated by the enhancer elements. Although proximal antigen-receptor signal transduction pathways are well defined, the precise nuclear factors targeted by these signals remained unknown. Previous studies have demonstrated that tissue-restricted transcription factors including
PU.1
and
PU.1
interaction partner (PIP) function synergistically with c-Fos plus
c-Jun
to stimulate the kappaE3'-enhancer in 3T3 cells. In this study, we demonstrate that the functional synergy between these factors is enhanced in response to mitogen-activated protein kinase kinase kinase, in 3T3 cells, where the enhancer is inactive. However in S194 plasmacytoma cells, mitogen-activated protein kinase kinase kinase was able to stimulate the activity of
PU.1
but unable to induce the kappaE3'-enhancer activity. We have found that Ras-phosphoinositide 3-kinase-dependent externally regulated kinase, AKT, induces kappaE3'-enhancer activity in both pre-B and plasmacytoma cells. AKT stimulation of the kappaE3'-enhancer is primarily due to
PU.1
induction and is independent of
PU.1
interaction with PIP. Activation of AKT had no effect on the expression levels of
PU.1
or its protein-protein interaction with PIP. Using a series of deletion constructs, we have determined that the
PU.1
acid-rich (amino acids 33-74) transactivation domain is necessary for AKT-mediated induction. Substitution analyses within this region indicate that phosphorylation of Ser(41) is necessary to respond to AKT. Consistent with these studies, ligation of antigen receptors in A20 B cells mimics AKT activation of
PU.1
. Taken together, these results provide evidence that
PU.1
is induced by AKT signal in a phosphoinositide 3-kinase-dependent manner, leading to inducible or constitutive activation of its target genes.
...
PMID:AKT induces transcriptional activity of PU.1 through phosphorylation-mediated modifications within its transactivation domain. 1113 86
Depriving primary bone marrow-derived macrophages of colony-stimulating factor-1 (CSF-1) induces programmed cell death by apoptosis. We show that cell death is accompanied by decreases in the expression of anti-apoptotic Bcl-x(L) protein and the Ets2 and
PU.1
proteins of the Ets transcription factor family. Macrophages require both priming and triggering signals independent of CSF-1 to kill neoplastic cells or microorganisms, and this activation of macrophage competence is accompanied by increased expression of bcl-x(L), ets2, and
PU.1
. Furthermore, we show that only Ets2 and
PU.1
, but not Ets1, function in a synergistic manner to transactivate the bcl-x promoter. The synergy observed between
PU.1
and Ets2 is dependent on the transactivation domains of both proteins. Although other transcription factors like Fos,
c-Jun
, Myc, STAT3, and STAT5a are implicated in the activation of macrophage competence or in CSF-1 signaling, no synergy was observed between Ets2 and these transcription factors on the bcl-x promoter. We demonstrate that the exogenous expression of both Ets2 and
PU.1
in macrophages increases the number of viable cells upon CSF-1 depletion and that Ets2 and
PU.1
can functionally replace Bcl-x(L) in inhibiting Bax-induced apoptosis. Together, these results demonstrate that
PU.1
and Ets2 dramatically increase bcl-x activation, which is necessary for the cytocidal function and survival of macrophages.
...
PMID:Bcl-XL expression correlates with primary macrophage differentiation, activation of functional competence, and survival and results from synergistic transcriptional activation by Ets2 and PU.1. 1127 99
Expression of the urokinase plasminogen activator (uPA) and its receptor (uPAR) correlates with tumour cell invasiveness and helps to determine the prognosis of prostate and other cancers. The purpose of this study was to establish in prostate cancer, the ets family and AP-1 complex transcription factors that might activate the inducible AP-1 and AP-1/PEA3 elements of the uPA enhancer. uPA and uPAR were expressed preferentially in adenocarcinoma cells, but not the stroma of high grade prostate cancers. The ets family paralogues Fli-1 and Elf-1 were also highly expressed in adenocarcinoma cells of the majority of cancers, while Erg 1,2 and Ets-2 were expressed in a minority of cancers and Elk-1, PEA3 and
PU.1
were minimally expressed. A minority of cancers expressed high levels of cytoplasmic and/or nuclear
c-Jun
and c-Fos transcription factors. We speculate as to the molecular basis for such expression.
...
PMID:Expression of urokinase plasminogen activator and receptor in conjunction with the ets family and AP-1 complex transcription factors in high grade prostate cancers. 1133 30
1
2
3
4
Next >>